Web31 jul. 2024 · Inotersen, an antisense oligonucleotide inhibitor of hepatic TTR production, demonstrated a favorable efficacy and safety profile in patients with the polyneuropathy associated with hATTR in the NEURO-TTR (NCT01737398) study. We report longer-term efficacy and safety data for inotersen, with a median treatment exposure of 3 years. … Web7 okt. 2024 · BOSTON, Mass. and NEW YORK, NY, October 7, 2024 – Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an …
Every Moment Matters Ionis
WebThe most common side effects were injection site reactions (such as redness or pain at the injection site), nausea, headache, tiredness, low platelet count (thrombocytopenia), and … Web9 apr. 2024 · Objective: To report the impact of inotersen, a transthyretin-directed antisense oligonucleotide indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, on neuropathy symptoms and change (NSC) scores in patients with hATTR amyloidosis as an exploratory outcome in a global, randomized, … ready faz bears pizzeria
About Akcea Ionis Pharmaceuticals, Inc.
Web6 mei 2024 · Inotersen (Tegsedi ®; Akcea Therapeutics, Inc, Boston, MA, USA and Ionis Pharmaceuticals, Carlsbad, CA, USA) was approved for the treatment of the … Web16 mrt. 2024 · March 16, 2024 Ionis and Akcea enter licensing deal for two rare disease drugs US-based Ionis Pharmaceuticals has exclusively out-licensed its antisense drug inotersen and AKCEA-TTR-L to Akcea Therapeutics under an … Web来源:SEC 整理:洞见研报 djyanbao.com 微信搜索「洞见研报」 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, … ready fiber